Vigil Neuroscience, Inc. (NASDAQ:VIGL – Get Free Report) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 884,100 shares, a decline of 20.4% from the July 15th total of 1,110,000 shares. Approximately 5.2% of the shares of the company are short sold. Based on an average daily volume of 563,800 shares, the days-to-cover ratio is presently 1.6 days.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Vigil Neuroscience by 11.9% in the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock valued at $3,050,000 after buying an additional 95,276 shares in the last quarter. Ensign Peak Advisors Inc raised its position in Vigil Neuroscience by 72.8% during the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after acquiring an additional 166,442 shares during the period. Renaissance Technologies LLC lifted its holdings in Vigil Neuroscience by 19.2% during the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock valued at $286,000 after purchasing an additional 11,536 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vigil Neuroscience in the second quarter valued at about $87,000. Finally, Strs Ohio purchased a new stake in shares of Vigil Neuroscience during the fourth quarter worth about $27,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.
Vigil Neuroscience Stock Up 18.5 %
Shares of NASDAQ VIGL traded up $0.54 during midday trading on Thursday, reaching $3.46. 270,334 shares of the stock were exchanged, compared to its average volume of 289,912. The firm has a 50-day simple moving average of $4.02 and a two-hundred day simple moving average of $3.44. Vigil Neuroscience has a twelve month low of $2.47 and a twelve month high of $9.24. The firm has a market cap of $130.04 million, a price-to-earnings ratio of -1.63 and a beta of 2.00.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on VIGL
About Vigil Neuroscience
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Featured Articles
- Five stocks we like better than Vigil Neuroscience
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- Best Aerospace Stocks Investing
- Jeff Brown’s Exegesis AI Stock Picks
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.